Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata

November 2025 in “ Clinical Cosmetic and Investigational Dermatology ”

Rongqiao He, Lynne Yao, N C Lan, Li Zhu, Yongmei Lv

TLDR Tofacitinib is effective and safe for treating severe alopecia areata.

This study presents a case series and literature review on the use of tofacitinib for treating severe alopecia areata (AA). The findings support the efficacy and safety of tofacitinib in managing this condition, adding to the clinical evidence for its application. The study highlights the potential of tofacitinib as a viable treatment option for patients with severe AA, although the document does not specify the number of participants involved in the case series.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

27 / 27 results

research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients

May 2024 in “Journal of cosmetic dermatology”

Tofacitinib is an effective and safe treatment for alopecia areata.

research Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review

September 2023 in “Acta dermato-venereologica”

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

research Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways

3 citations , July 2023 in “International journal of molecular sciences”

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

research Oxidative Stress and Alopecia Areata

3 citations , June 2023 in “Frontiers in medicine”

Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.

research Baricitinib as the First Systemic Treatment for Severe Alopecia Areata

2 citations , April 2023 in “Expert Review of Clinical Immunology”

Baricitinib is effective as a treatment for severe hair loss.

research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review

2 citations , April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “Indian Dermatology Online Journal”

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

research Lifestyle Factors Involved in the Pathogenesis of Alopecia Areata

16 citations , January 2022 in “International journal of molecular sciences”

Certain daily habits like stress, diet, and sleep can affect the severity of hair loss in alopecia areata.

research The JAK/STAT Signaling Pathway: From Bench to Clinic

489 citations , November 2021 in “Signal Transduction and Targeted Therapy”

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

research Oral Tofacitinib for the Treatment of Alopecia Areata in Pediatric Patients

13 citations , November 2021 in “Pediatric Dermatology”

Tofacitinib taken by mouth helps treat hair loss in children.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses

11 citations , February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

research Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata

9 citations , October 2019 in “Dermatologic Therapy”

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , September 2019 in “Journal of the European Academy of Dermatology and Venereology”

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

research Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata

11 citations , November 2018 in “Journal of the American Academy of Dermatology”

Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.

research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children

40 citations , September 2018 in “Journal of the American Academy of Dermatology”

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , February 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research The Role of Micronutrients in Alopecia Areata: A Review

63 citations , May 2017 in “American Journal of Clinical Dermatology”

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Genomewide Analysis of Copy Number Variants in Alopecia Areata in a Central European Cohort Reveals Association with MCHR2

29 citations , June 2016 in “Experimental Dermatology”

MCHR2 gene duplications may be linked to alopecia areata.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , June 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

research Genomewide Scan for Linkage Reveals Evidence of Several Susceptibility Loci for Alopecia Areata

143 citations , January 2007 in “The American Journal of Human Genetics”

Certain genes on chromosomes 6, 10, 16, and 18 may increase the risk of alopecia areata.

Similar Research

6 / 878 results

research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses

11 citations , February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report

26 citations , October 2016 in “Case Reports in Dermatology”

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

8 citations , June 2022 in “Frontiers in Medicine”

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome

April 2023 in “Dermato”

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study

49 citations , August 2018 in “International Journal of Dermatology”

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib

9 citations , April 2018 in “Journal of Dermatological Treatment”

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.